Janney Montgomery Scott upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Buy with a price target of $65.00.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

Upgrades

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - OppenheimerSeptember 20, 2016 1:18 PM Sarepta Therapeutic (SRPT) PT Raised to $66 at WedbushSeptember 20, 2016 7:21 AM RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A TargetSeptember 19, 2016 1:52 PM Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & CompanySeptember 19, 2016 1:37 PM Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market PerformSeptember 19, 2016 1:29 PM Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen ApprovalSeptember 19, 2016 1:08 PM Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%September 19, 2016 11:21 AM FDA Approves Sarepta Therapeutics' (SRPT) EteplirsenSeptember 19, 2016 9:52 AM Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for EteplirsenSeptember 19, 2016 9:51 AM